AI-generated · cited to primary sources · not investment advice
Tempus AI, Inc. - Class A Common Stock (TEM) Mar 2025 Filing Analysis
Does management do what it says?
The agreement is active with $70 million paid upon execution. The commitment floor of $180 million remains in effect through 2027. (4 in progress across 4 tracked commitments)
“In exchange for certain discounted prices, GSK has committed to spend a minimum of $180 million on such products and services during the term of the GSK Agreement... The term of the GSK Agreement will continue through December 31, 2027”
The company has received the initial $50 million upfront payment as of April 2025 and has recognized $41.7 million in revenue from Pathos for the nine months ended September 30, 2025. (2 in progress across 2 tracked commitments)
“We expect to maintain high levels of investment in product innovation over the coming years as we continue to develop new laboratory assays, develop algorithms, and expand our Platform into new disease areas.”
See the full cited Management analysis of Tempus AI, Inc. - Class A Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.